Amylyx Pharmaceuticals, Inc.

SecurityAMLX / Amylyx Pharmaceuticals, Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership31,782 shares
Latest Disclosed Value $ 441,770
Citigroup Inc ownership in AMLX / Amylyx Pharmaceuticals, Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 31,782 shares of Amylyx Pharmaceuticals, Inc. (US:AMLX) valued at $441,770 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 38,032 shares of Amylyx Pharmaceuticals, Inc.. This represents a change in shares of -16.43% during the quarter. The current value of the position is $419,522 USD.

Citigroup Inc has a history of taking positions in derivatives of the underlying security (AMLX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

AMLX / Amylyx Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 31,782 -6,250 -16.43 442 -3.92 0.0002
2026-02-13 2025-12-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 38,032 -51 -0.13 459 -11.22 0.0002
2025-11-10 2025-09-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 38,083 6,985 22.46 518 159.80 0.0002
2025-08-11 2025-06-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 31,098 -432,142 -93.29 199 -87.86 0.0001
2025-05-12 2025-03-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 463,240 -146,084 -23.97 1,640 -28.83 0.0008
2025-02-12 2024-12-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 609,324 34,319 5.97 2,303 23.62 0.0014
2024-11-12 2024-09-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 575,005 -88,371 -13.32 1,863 47.86 0.0011
2024-08-12 2024-06-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 663,376 -251,351 -27.48 1,260 -51.48 0.0008
2024-05-10 2024-03-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 914,727 527,063 135.96 2,598 -54.49 0.0017
2024-02-09 2023-12-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 387,664 343,875 785.30 5,706 612.36 0.0040
2023-12-06 2023-09-30 13F/A-1 AMYLYX PHARMACEUTICALS COM 03237H101 43,789 -33,780 -43.55 802 -52.12 0.0006
2023-11-09 2023-09-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 43,789 802
2023-08-10 2023-06-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 77,569 44,443 134.16 1,673 72.30 0.0011
2023-05-11 2023-03-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 33,126 23,403 240.70 972 170.47 0.0007
2023-02-09 2022-12-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 9,723 1,002 11.49 359 46.53 0.0003
2022-11-10 2022-09-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 8,721 7,886 944.43 245 1,431.25 0.0002
2022-08-10 2022-06-30 13F AMYLYX PHARMACEUTICALS COM 03237H101 835 -319 -27.64 16 6.67 0.0000
2022-05-12 2022-03-31 13F AMYLYX PHARMACEUTICALS COM 03237H101 1,154 1,154 15 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-05-10 2024-03-31 13F AMYLYX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-02-09 2023-12-31 13F AMYLYX PHARMACEUTICALS COM Call 71,700 23.20 1,055 -0.94 n/a n/a n/a
2023-12-06 2023-09-30 13F/A AMYLYX PHARMACEUTICALS COM Call 58,200 -4.12 1,066 -18.64 n/a n/a n/a
2023-11-09 2023-09-30 13F AMYLYX PHARMACEUTICALS COM Call 58,200 1,066 n/a n/a n/a
2023-08-10 2023-06-30 13F AMYLYX PHARMACEUTICALS COM Call 60,700 1,114.00 1,309 796.58 n/a n/a n/a
2023-05-11 2023-03-31 13F AMYLYX PHARMACEUTICALS COM Call 5,000 -90.58 147 -92.56 n/a n/a n/a
2023-02-09 2022-12-31 13F AMYLYX PHARMACEUTICALS COM Call 53,100 -27.95 1,962 -5.45 n/a n/a n/a
2022-11-10 2022-09-30 13F AMYLYX PHARMACEUTICALS COM Call 73,700 2,075 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-05-10 2024-03-31 13F AMYLYX PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-02-09 2023-12-31 13F AMYLYX PHARMACEUTICALS COM Put 71,700 23.20 1,055 -0.94 n/a n/a n/a
2023-12-06 2023-09-30 13F/A AMYLYX PHARMACEUTICALS COM Put 58,200 -4.12 1,066 -18.64 n/a n/a n/a
2023-11-09 2023-09-30 13F AMYLYX PHARMACEUTICALS COM Put 58,200 1,066 n/a n/a n/a
2023-08-10 2023-06-30 13F AMYLYX PHARMACEUTICALS COM Put 60,700 102.33 1,309 48.75 n/a n/a n/a
2023-05-11 2023-03-31 13F AMYLYX PHARMACEUTICALS COM Put 30,000 -43.50 880 -55.15 n/a n/a n/a
2023-02-09 2022-12-31 13F AMYLYX PHARMACEUTICALS COM Put 53,100 -55.34 1,962 -41.38 n/a n/a n/a
2022-11-10 2022-09-30 13F AMYLYX PHARMACEUTICALS COM Put 118,900 3,347 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.